Kim A. Connelly

FRACP, PhD, MBBS

Scientist

Biography

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with significant research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes.

His H index is 45, and I index of 140.

Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.

Recent Publications

  1. Schlotter, F, Miura, M, Kresoja, KP, Alushi, B, Alessandrini, H, Attinger-Toller, A et al.. Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. EuroIntervention. 2021; :. doi: 10.4244/EIJ-D-21-00191. PubMed PMID:33956637 .
  2. Yerra, VG, Batchu, SN, Kabir, G, Advani, SL, Liu, Y, Siddiqi, FS et al.. Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. Cardiovasc Drugs Ther. 2021; :. doi: 10.1007/s10557-021-07190-2. PubMed PMID:33886003 .
  3. Hassanin, M, Ong, G, Connelly, KA. Right ventricle longitudinal strain, a new tool in functional tricuspid regurgitation prognostication. Can J Cardiol. 2021; :. doi: 10.1016/j.cjca.2021.04.001. PubMed PMID:33845137 .
  4. Nouraei, H, Leiter, LA, Tan, MK, Langer, A, Teoh, H, Cheng, AYY et al.. Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Can J Diabetes. 2021; :. doi: 10.1016/j.jcjd.2021.02.003. PubMed PMID:33839025 .
  5. Meagher, PB, Lee, XA, Lee, J, Visram, A, Friedberg, MK, Connelly, KA et al.. Cardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling. Cells. 2021;10 (4):. doi: 10.3390/cells10040770. PubMed PMID:33807373 PubMed Central PMC8066890.
  6. Weissler Snir, A, Connelly, KA, Goodman, JM, Dorian, D, Dorian, P. Exercise in Hypertrophic Cardiomyopathy: Restrict or Rethink??. Am J Physiol Heart Circ Physiol. 2021; :. doi: 10.1152/ajpheart.00850.2020. PubMed PMID:33769918 .
  7. Kitamura, M, Fam, NP, Braun, D, Ruf, T, Sugiura, A, Narang, A et al.. 12-Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation. Catheter Cardiovasc Interv. 2021;97 (6):1281-1289. doi: 10.1002/ccd.29583. PubMed PMID:33660364 .
  8. Muntané-Carol, G, Taramasso, M, Miura, M, Gavazzoni, M, Pozzoli, A, Alessandrini, H et al.. Transcatheter Tricuspid Valve Intervention in Patients with Previous Left Valve Surgery. Can J Cardiol. 2021; :. doi: 10.1016/j.cjca.2021.02.010. PubMed PMID:33617978 .
  9. Muntané-Carol, G, Taramasso, M, Miura, M, Gavazzoni, M, Pozzoli, A, Alessandrini, H et al.. Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry. Circ Cardiovasc Interv. 2021;14 (2):e009685. doi: 10.1161/CIRCINTERVENTIONS.120.009685. PubMed PMID:33541097 .
  10. Ong, G, Connelly, KA. No longer the "forgotten valve? Tricuspid Regurgitation Management and Outcomes: Narrowing the Knowledge Gap One Step at a Time. Can J Cardiol. 2021; :. doi: 10.1016/j.cjca.2021.01.022. PubMed PMID:33539989 .
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre
X